Medicatons

Bisphosphonate therapy is the most common pharmacologic treatment for osteoporosis.  This class of drugs inhibits the function of osteoclasts, which are the cells responsible for bone resorption or breakdown.  Some common oral bisphosphonates include Sodium Alendronate (Fosamax), Risedronate (Actonel) and Ibandronate (Boniva).  These need to be taken either daily, weekly or monthly. Some people experience GI side effects while taking these oral bisphosphonates, so please consult with your physician if you experience any symptoms. 

Aclasta is a once-yearly bisphosphonate which is infused intravenously, directly entering the bloodstream.  Since Aclasta is administered IV, it bypasses the GI tract, eliminating potential absorption limitations.  This drug is 100% bioavailable in a single dose and has been shown to significantly reduce the risk of hip, spine and other fractures.  It is an effective therapy for the treatment and prevention of osteoporosis in post menopausal women

Tariparatide (Forteo) is a recombinant form of parathyroid hormone and is used as a treatment for people with severe osteoporosis who are at high risk for fracture. Teriparatide is administered by injection once a day in the thigh or abdomen.  Intermittent exposure to Teriparatide has been shown to stimulate osteoblasts (bone building cells) more than osteoclasts (bone resorping cells), stimulating new bone formation.

Selective estrogen receptor modulators (SERMs) are molecules that exert estrogenic effects by binding to the estrogen receptor.  These molecules act as estrogen agonists in the bone (stimulate bone formation), but act as antagonists in the reproductive tissues (breast and uterus).  Thus, there are fewer side effects with the use of SERMs than with the use of HRT. Raloxifene (Evista) is indicated for the prevention of osteoporosis in post menopausal women as it has been shown to slow bone resorption by the osteoclasts.